PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Albert Grass und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Phillips University Marburg und University Hospital Marburg, Marburg, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Pancreatic Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
As neuroendocrine tumors (NETs) often present as metastatic lesions, immunohistochemical assignment to a site of origin is one of the most important tasks in their pathologic assessment. Because a fraction of NETs eludes the typical expression profiles of their primary localization, additional sensitive and specific markers are required to improve diagnostic certainty. We investigated the expression of the transcription factor Pituitary Homeobox 2 (PITX2) in a large-scale cohort of 909 NET and 248 neuroendocrine carcinomas (NEC) according to the immunoreactive score (IRS) and correlated PITX2 expression groups with general tumor groups and primary localization. PITX2 expression (all expression groups) was highly sensitive (98.1%) for midgut-derived NET, but not perfectly specific, as non-midgut NET (especially pulmonary/duodenal) were quite frequently weak or moderately positive. The specificity rose to 99.5% for a midgut origin of NET if only a strong PITX2 expression was considered, which was found in only 0.5% (one pancreatic/one pulmonary) of non-midgut NET. In metastases of midgut-derived NET, PITX2 was expressed in all cases (87.5% strong, 12.5% moderate), whereas CDX2 was negative or only weakly expressed in 31.3% of the metastases. In NEC, a fraction of cases (14%) showed a weak or moderate PITX2 expression, which was not associated with a specific tumor localization. Our study independently validates PITX2 as a very sensitive and specific immunohistochemical marker of midgut-derived NET in a very large collective of neuroendocrine neoplasms. Therefore, our data argue toward implementation into diagnostic panels applied for NET as a firstline midgut marker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Phillips University Marburg und University Hospital Marburg, Marburg, Germany.
- Department of Pathology, Technical University of Munich, Munich, Germany.
- Department of Pathology, University Hospital Mainz, Mainz, Germany.
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Surgery, Phillips University Marburg and University Hospital Marburg, Marburg, Germany.
- Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Zitieren
APA
Grass, A., Kasajima, A., Foersch, S., Kriegsmann, M., Brobeil, A., Schmitt, M., Wagner, D., Poppinga, J., Wiese, D., Maurer, E., Kirschbaum, A., Muley, T., Winter, H., Rinke, A., Gress, T. M., Kremer, M., Evert, M., Märkl, B., Quaas, A., …, & Jesinghaus, M. (2024). PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100442
Vancouver
Grass A, Kasajima A, Foersch S, Kriegsmann M, Brobeil A, Schmitt M, et al. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100442
BibTeX
@article{Grass2024,
author = {Grass, Albert and Kasajima, Atsuko and Foersch, Sebastian and Kriegsmann, Mark and Brobeil, Alexander and Schmitt, Maxime and Wagner, Daniel and Poppinga, Jelte and Wiese, Dominik and Maurer, Elisabeth and Kirschbaum, Andreas and Muley, Thomas and Winter, Hauke and Rinke, Anja and Gress, Thomas M and Kremer, Markus and Evert, Matthias and Märkl, Bruno and Quaas, Alexander and Eckstein, Markus and Tschurtschenthaler, Markus and Klöppel, Günter and Denkert, Carsten and Bartsch, Detlef K and Jesinghaus, Moritz},
title = {PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100442}
}
EUVIMED